Secondary Use of PARALLEL-HF Data

This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to assess the effect of sacubitril valsartan at a target dose of 200 mg b.i.d. and enalapril 10 mg b.i.d. on cardiovascular (CV) mortality and morbidity in Japanese HF patients with reduced ejection fraction.

NCT Number	NCT07527767
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Enrollment	236 participants
Start Date	2022-07-27
Primary Completion	2023-12-15 (estimated)
Study Completion	2023-12-15 (estimated)
Updated on ClinicalTrials.gov	2026-04-14